Table 1.
Characteristics of the population
| N (%) | Median | Mean [SD] | |
|---|---|---|---|
| Clinical characteristics | |||
| Sex: male | 10 (43.5) | ||
| Age (years) | 44.2 [± 9.78] | ||
| Symptom duration (years) | 7.7 [± 8.5] | ||
| Axial involvement | 12(52.2) | ||
| Tobacco use | 16 (70) | ||
| Treatment | |||
| NSAIDs | 18 (78.3%) | ||
| TNF blockers* | 4 (17.4%) | ||
| Biological results | |||
| Sedimentation rate (mm at the first hour) | 14 | 23.3 [± 22.6] | |
| CRP (mg/mL) | 8 | 14.4 [± 20.6] | |
| ASAS criteria | |||
| HLA-B27 | 7 (30.4) | ||
| Arthritis | 9 (39.1) | ||
| Enthesitis | 8 (38.8) | ||
| Uveitis | 2 (8.7) | ||
| Dactylitis | 2 (8.7) | ||
| Psoriasis | 6 (26.1) | ||
| Inflammatory bowel disease | 3 (13.0) | ||
| Familial history | 4 (17.4) | ||
| Inflammatory back pain | 22 (95.7) | ||
| Good response to NSAIDs | 11 (47.8) | ||
| Biological inflammation (CRP > 5 mg/L) | 12 (52.2) | ||
| Clinical evaluation scores** | |||
| BASFI | 61.5 | 59.3 [± 23.0] | |
| BASDAI | 5.88 | 5.45 [± 2.57] | |
| BASMI | 3 | 2.9 [± 2.0] | |
| ASDAS | 3 | 3.3 [± 0.9] | |
*Anti-TNF: stopped 3 months before the MRI
**BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Activity Functional Index, BASMI Bath Ankylosing Metrology Index, ASDAS Ankylosing Spondylitis Disease Activity Score